A5069327867- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Genetic factors in colorectal cancer
- Epigenetics and DNA Methylation
- Urological Disorders and Treatments
- Renal and related cancers
- Pelvic floor disorders treatments
- Multiple and Secondary Primary Cancers
- Fibroblast Growth Factor Research
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Urologic and reproductive health conditions
- Urinary Bladder and Prostate Research
- Ureteral procedures and complications
- Testicular diseases and treatments
- Enhanced Recovery After Surgery
- Esophageal Cancer Research and Treatment
- Ferroptosis and cancer prognosis
- Colorectal Cancer Screening and Detection
- Urinary Tract Infections Management
- Cancer Research and Treatments
Columbia University Irving Medical Center
2023-2025
Columbia University
2024-2025
Texas Health Dallas
2025
Memorial Sloan Kettering Cancer Center
2021-2024
University of California, Los Angeles
2014-2023
Kettering University
2022
UCLA Health
2021
Los Angeles Medical Center
2020
Seattle University
2020
Shadyside Hospital
2020
The role of prostate-specific membrane antigen (PSMA)-targeted PET in comparison to mpMRI the evaluation intraprostatic cancer foci is not well defined. aim our study was compare diagnostic performances PSMA PET/CT, and PET/CT+mpMRI using 3 independent blinded readers for each modality with histopathology as gold standard detection, intra-prostatic localization local extension primary prostate cancer. <b>Methods:</b> Patients intermediate- or high-risk who underwent a PET/CT part prospective...
Abstract Purpose: Erdafitinib is the only FDA-approved targeted therapy for FGFR2/3-altered metastatic urothelial cancer. We characterized genetic landscape of FGFR-altered carcinoma and real-world clinical outcomes with erdafitinib, including on-treatment genomic evolution. Experimental Design: Prospectively collected data were integrated institutional to define carcinoma. To identify mechanisms erdafitinib resistance, a subset patients underwent prospective cell-free (cf) DNA assessment....
Pelvic organ prolapse is a vaginal protrusion of female pelvic organs. It has high prevalence worldwide and represents great burden to the economy. The pathophysiology multifactorial includes genetic predisposition, aberrant connective tissue, obesity, advancing age, delivery other risk factors. Owing long course prior patients becoming symptomatic ethical questions surrounding human studies, animal models are necessary useful. These can mimic different characteristics - histological,...
Abstract Cancers arising from the bladder urothelium often exhibit lineage plasticity with regions of urothelial carcinoma adjacent to or admixed divergent histomorphology, most commonly squamous differentiation. To define biologic basis for and clinical significance this morphologic heterogeneity, here we perform integrated genomic analyses mixed histology cancers separable We find that differentiation is a marker intratumoral immunologic heterogeneity in patients cancer biomarker intrinsic...
Patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab. We define the genomic features, clinical course, response to immune checkpoint blockade (ICB) in patients MSI-H/dMMR TMB-H without MSI [TMB-H/microsatellite stable (MSS)].
PURPOSE To compare oncologic outcomes and genomic alteration profiles in patients with bladder urachal adenocarcinoma, urothelial carcinoma (UC) glandular differentiation, UC, not otherwise specified (NOS) undergoing surgical resection, emphasis on response to systemic therapy. METHODS We identified cancer variants who underwent resection at Memorial Sloan Kettering from 1995 2018 (surgical cohort) and/or had tumor sequencing using a targeted next-generation platform (genomics cohort)....
TPS882 Background: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) remains the standard of care for muscle-invasive bladder cancer (MIBC) – a disease with median diagnosis age 73 years old. While curative, RC negatively impacts quality life and conveys significant rates morbidity (60%) mortality (5%), highlighting need preservation. Several trials have shown curative potential NAC (Grossman, NEJM 2003), immunotherapy (Necchi, JCO 2018), chemoimmunotherapy (Galsky, Nat Med...